Fig. 1: Mass spectrometry analysis of MM-MSCs demonstrated increase in mitochondrial-related metabolic pathways and proteins. | Oncogenesis

Fig. 1: Mass spectrometry analysis of MM-MSCs demonstrated increase in mitochondrial-related metabolic pathways and proteins.

From: Myeloma mesenchymal stem cells’ bioenergetics afford a novel selective therapeutic target

Fig. 1: Mass spectrometry analysis of MM-MSCs demonstrated increase in mitochondrial-related metabolic pathways and proteins.

A Principal component analysis (PCA) graph presents clear segregation of MM-MSCs and ND-MSCs mass spectrometry data according to source. B The BM-MSCs (ND and MM-MSCs) mass spectrometry data (differentially expressed proteins, p < 0.05 (FDR), N = 3 each) was assessed for cellular component and pathways using WebGestalt. Pie graphs present the percentage of metabolism-related GO pathways (red) out of all cell pathways (Cyan) in BM-MSCs. C STRING functional enrichment analysis of BM-MSCs upregulated proteins (FC ≥ 1.25, p < 0.05) included in the “Mitochondrion” cellular component STRING category (p = 2.16E−17, red nodes). D Median values of 63 protein levels (mass spectrometry) included in the BM-MSCs “Mitochondrion” cellular component category (WebGestalt, GO:0005739, p = 0) presented individually by shape and color.

Back to article page